Chemotherapy for thymic tumors: induction, consolidation, palliation

Thorac Surg Clin. 2011 Feb;21(1):107-14, viii. doi: 10.1016/j.thorsurg.2010.08.003.

Abstract

Although thymoma and thymic carcinoma are rare malignancies, they constitute a large proportion of tumors of the anterior mediastinum. Surgery forms the mainstay of therapy; however, thymic malignancies are sensitive to chemotherapy and radiation therapy also. Systemic chemotherapy is primarily used for treatment of metastatic or recurrent disease. Chemotherapy is also used as a component of multimodality treatment in the neoadjuvant setting with the aim of increasing the chances of achieving a complete surgical resection. In this article we outline various clinical trials that have been performed to evaluate the role of chemotherapy in the treatment of thymic malignancies.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Capecitabine
  • Cisplatin / therapeutic use
  • Clinical Trials as Topic
  • Cyclophosphamide / therapeutic use
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Doxorubicin / therapeutic use
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Gemcitabine
  • Humans
  • Methotrexate / therapeutic use
  • Neoadjuvant Therapy
  • Palliative Care
  • Procarbazine / therapeutic use
  • Thymoma / drug therapy*
  • Thymoma / mortality
  • Thymoma / radiotherapy
  • Thymoma / surgery
  • Thymus Neoplasms / drug therapy*
  • Thymus Neoplasms / mortality
  • Thymus Neoplasms / radiotherapy
  • Thymus Neoplasms / surgery
  • Vincristine / therapeutic use

Substances

  • Deoxycytidine
  • Procarbazine
  • Vincristine
  • Capecitabine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Fluorouracil
  • Methotrexate
  • Gemcitabine

Supplementary concepts

  • ADOC protocol
  • CAMP protocol